Cargando…
SARS Vaccine Development
Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)–associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main c...
Autores principales: | Jiang, Shibo, He, Yuxian, Liu, Shuwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371787/ https://www.ncbi.nlm.nih.gov/pubmed/16022774 http://dx.doi.org/10.3201/eid1107.050219 |
Ejemplares similares
-
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
por: Du, Lanying, et al.
Publicado: (2009) -
Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine
por: He, Yuxian, et al.
Publicado: (2004) -
Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines
por: He, Yuxian, et al.
Publicado: (2005) -
Multistate Outbreak of SARS-CoV-2 Infections, Including Vaccine Breakthrough Infections, Associated with Large Public Gatherings, United States
por: Gharpure, Radhika, et al.
Publicado: (2022) -
Review of Bats and SARS
por: Wang, Lin-Fa, et al.
Publicado: (2006)